PTPRC and neoplasm: Compared with the controls (vehicle or no treatment), SLR14 treatment induced a significant increase of tumor-infiltrating CD45+ leukocytes, including CD11b+ myeloid cells, CD8+ T cells, and NK1.1+ cells, whereas CD4+ cells or CD4+FoxP3+ T reg cells were significantly decreased (Fig. 5 A, top).